Back to catalog
SLU-PP-332 3ml vial label
MetabolicPurity 98.0%
Product profile

SLU-PP-332

Pan-ERR agonist mimicking endurance-exercise signaling.

98.0%
Purity
Lyophilized
Form
-20°C
Storage
Research Use Only. Not for human or veterinary consumption, diagnostic, or therapeutic use.

What it is

SLU-PP-332 is a pan-agonist of the estrogen-related receptors (ERRα/β/γ) studied as an exercise-mimetic for metabolic and endurance research.

Pathway Diagram

Mechanism of Action

CRL · MOA-01

Activates ERR transcriptional programs governing mitochondrial biogenesis, fatty-acid oxidation and oxidative-fiber gene expression.

  1. Step 01
    Receptor Binding

    Peptide engages target receptor with high affinity.

  2. Step 02
    Signal Cascade

    Downstream intracellular pathways activate.

  3. Step 03
    Cellular Response

    Gene expression and protein synthesis shift.

  4. Step 04
    Observed Outcome

    Measurable change in the studied biomarker.

Primary TargetsMitochondrial biogenesisEndurance researchObesity & metabolic studies

Research highlights

Pan-ERR (α/β/γ) agonist — first chemical exercise-mimetic of this class.
Activates mitochondrial-biogenesis transcriptional program.
Increases endurance capacity in untrained mice without exercise.
Reduces fat mass and improves glycemic markers in DIO models.

Pharmacology snapshot

377.5 Da
Molecular weight
Short (small molecule, research)
Half-life
Oral / IP (research)
Route (research)

Potential research applications

Mitochondrial biogenesis
Endurance research
Obesity & metabolic studies
Skeletal-muscle remodeling

Case studies

PreclinicalMulti-week

ERR agonist in metabolic syndrome

Cohort: DIO mice

Tested SLU-PP-332 in diet-induced obesity model.

Outcome

Reduced body weight and fat mass with improved glycemic control.

Billon et al., J Pharmacol Exp Ther 2023;388(2):232–240
In vivoDays–weeks

Endurance capacity enhancement

Cohort: Mice (treadmill)

Quantified endurance performance under SLU-PP-332 without training.

Outcome

Significant increase in running time and distance vs. vehicle.

Billon et al., Nat Metab 2024;6:60–73
Preclinical

ERR biology in metabolic control

Cohort: Cross-tissue synthesis

Reviewed ERRα/γ biology relevant to ERR-agonist class.

Outcome

Established ERR pathway as central regulator of oxidative-fiber metabolism.

Audet-Walsh & Giguère, Acta Pharmacol Sin 2015;36(1):51–61
Handling Protocol

Storage Guidelines

CRL · STR-02

Store at -20°C, desiccated and light-protected.

Lyophilized
-20°C
Long-term, 24 months
Reconstituted
2–8°C
Refrigerated, 28 days
Light Exposure
Protect
Store in dark vial
Diluent
BAC Water
Sterile, 0.9% benzyl
Best practice — reconstitute with bacteriostatic water, swirl gently, do not shake.
Regulatory Notice

Research Disclaimer

CRL · REG-03
Research Use Only

Strictly for in-vitro laboratory and research investigations.

Not For Human Use

Not approved for diagnostic, therapeutic, or veterinary application.

Qualified Personnel

Handling restricted to licensed researchers and laboratory staff.

Warning — SLU-PP-332 is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.

Document · CRL-REG-03Revision 2026.06 · Clinical Research Labs
Representative Literature

Citations & References

CRL · REF-04
  1. 01
    Billon C, Sitaula S, Banerjee S, et al. · 2023
    A synthetic ERR agonist alleviates metabolic syndrome
    J Pharmacol Exp Ther. 388(2):232–240.
References are representative of peer-reviewed literature and are provided for research context only.
Document · CRL-REF-04Revision 2026.06 · Clinical Research Labs